Page last updated: 2024-10-15
divercin v41
Description
divercin V41: isolated from Carnobacterium divergens; amino acid sequence in first source; GenBank AJ224003 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 139583212 |
| MeSH ID | M0299217 |
Synonyms (1)
Research Excerpts
Overview
Divercin V41 (DvnV41) is a class IIa bacteriocin with potent antilisterial activity isolated from Carnobacterium divergens V41.
| Excerpt | Reference |
|---|
| "Divercin V41 (DvnV41) is a class IIa bacteriocin with potent antilisterial activity isolated from Carnobacterium divergens V41. " | ( Insights into structure-activity relationships in the C-terminal region of divercin V41, a class IIa bacteriocin with high-level antilisterial activity.
Demnerova, K; Drider, D; Petit, VW; Prévost, H; Rebuffat, S; Rihakova, J, 2009) |
| "Divercin V41 is a class IIa bacteriocin produced by Carnobacterium divergens V41 with a strong anti-Listeria activity. " | ( Antimicrobial activity of divercin RV41 produced and secreted by Lactococcus lactis.
Bermúdez-Humarán, LG; Demnerova, K; Drider, D; Langella, P; Nazef, L; Prévost, H; Rihakova, J, 2007) |
| "Divercin V41 is a new bacteriocin produced by Carnobacterium divergens V41, a lactic acid bacterium isolated from fish viscera. " | ( Divercin V41, a new bacteriocin with two disulphide bonds produced by Carnobacterium divergens V41: primary structure and genomic organization.
Anglade, P; Cenatiempo, Y; Dousset, X; Fremaux, C; Marlon, D; Metivier, A; Piard, JC; Pilet, MF; Sorokine, O; Zagorec, M, 1998) |
| "Divercin V41 (DV41) is a class IIa bacteriocin produced by Carnobacterium divergens V41. " | ( Delineation of key amino acid side chains and peptide domains for antimicrobial properties of divercin V41, a pediocin-like bacteriocin secreted by Carnobacterium divergens V41.
Bhugaloo-Vial, P; Boyaval, P; Douliez, JP; Dousset, X; Marion, D; Moll, D, 1999) |
Research
Studies (20)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.00) | 18.2507 |
| 2000's | 15 (75.00) | 29.6817 |
| 2010's | 2 (10.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (5.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (95.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |